It is the broad, long-term goal of this program to build on and extend current knowledge in the field of stem cell transplantation with a focus on hemato-lymphoid diseases. While the use of high dose therapy with hematopoietic support has resulted in improved outcome in selected patients, the relapse rate in those treated late in the course of their disease remains high. To this end, the investigators of this renewal application will utilize the approach of translational research, bridging novel experimental concepts and observations made at the laboratory bench to clinical application at the patient's bedside. This program project will focus on the use and understanding of stem cell transplantation in an attempt to achieve a complete or near complete remission followed by novel manipulations to maintain the remission, thus improving the clinical outcome for our patients. The major hypothesis to be tested is whether a step wise process in engineering a haploidentical graft will ensure donor engraftment without graft-versus-host disease (GVHD) but at the same time, enhancing immune recovery and anti tumor effects of the allogeneic transplant. Project I will focus on the clinical projects to improve the outcomes of haploidentical transplantation and post transplant cellular strategies. Project II will continue to develop the use of naive T cell depletion to decrease GVHD and ascertain if memory T cells can enhance immune recovery. Project will determine the utility of toll like receptors (TLRs) in enhancing vaccine strategies. The interplay of innate and the adaptive immune system with the process of graft engineering and adoptive cellular therapy is a major strength of the scientists in this application. The extensive on going discussions and the strong interactions among the projects and cores create an exciting synergy that will lead to important results. Our commitment to patients'welfare and improved outcomes continues to drive our efforts. The lessons learned from these studies will also be applicable to other forms of allogeneic hematopoietic cell transplantation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (J1))
Program Officer
Merritt, William D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Brunger, Jonathan M; Huynh, Nguyen P T; Guenther, Caitlin M et al. (2014) Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage. Proc Natl Acad Sci U S A 111:E798-806
Kanda, Junya; Long, Gwynn D; Gasparetto, Cristina et al. (2014) Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies. Biol Blood Marrow Transplant 20:257-63
Brandstadter, Joshua D; Huang, Xiaopei; Yang, Yiping (2014) NK cell-extrinsic IL-18 signaling is required for efficient NK-cell activation by vaccinia virus. Eur J Immunol 44:2659-66
Macintyre, Andrew N; Gerriets, Valerie A; Nichols, Amanda G et al. (2014) The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab 20:61-72
Horwitz, Mitchell E; Chao, Nelson J; Rizzieri, David A et al. (2014) Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest 124:3121-8
Glass, Katherine A; Link, Jarrett M; Brunger, Jonathan M et al. (2014) Tissue-engineered cartilage with inducible and tunable immunomodulatory properties. Biomaterials 35:5921-31
Chen, Benny J; Jiao, Yiqun; Zhang, Ping et al. (2013) Long-term in vivo imaging of multiple organs at the single cell level. PLoS One 8:e52087
Kanda, J; Kaynar, L; Kanda, Y et al. (2013) Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. Bone Marrow Transplant :
Fortin, Carl; Huang, Xiaopei; Yang, Yiping (2013) Both NK cell-intrinsic and -extrinsic STAT1 signaling are required for NK cell response against vaccinia virus. J Immunol 191:363-8
Kanda, J; Horwitz, M E; Long, G D et al. (2012) Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 47:700-5

Showing the most recent 10 out of 92 publications